BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15083598)

  • 1. Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
    Boersma E; Westerhout CM
    Curr Opin Investig Drugs; 2004 Mar; 5(3):313-9. PubMed ID: 15083598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
    Koller CF
    Heart Lung; 2001; 30(5):321-9; quiz 330-1. PubMed ID: 11604974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
    Dobesh PP; Latham KA
    Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
    Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
    Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.
    Chew DP; Roffi M; Topol EJ
    Prog Cardiovasc Dis; 2001; 44(3):195-206. PubMed ID: 11727277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Subbarao VD; Phillips J; Stouffer GA
    Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Westerhout CM; Boersma E
    Expert Opin Drug Saf; 2003 Jan; 2(1):49-58. PubMed ID: 12904124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of GP IIb/IIIa blockers in clinical cardiology].
    Rossi ML; Merlini PA
    Recenti Prog Med; 2003 Oct; 94(10):440-3. PubMed ID: 14619191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of acute ischaemic coronary syndromes beyond aspirin therapy: role of glycoprotein IIb/IIIa antagonists.
    Gambhir DS
    Indian Heart J; 1998; 50(2):151-4. PubMed ID: 9622980
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
    Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
    J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.